

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5160
(“Mediclinic”, the “Company” or the “Group”)

26 July 2017

ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS

Mediclinic announces that at its Annual General Meeting (“AGM”) held on 25 July 2017, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:

		TOTAL SHARES VOTED	% OF ISSUED SHARE CAPITAL VOTED	VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD
	ORDINARY RESOLUTIONS							
1.	To receive the Company’s financial statements and the reports by the Directors and auditors	643,346,097	87.26%	642,608,938	99.99%	211	0.01%	736,948
2.	To approve the Directors’ Remuneration Report	643,346,097	87.26%	618,212,690	96.25%	24,075,900	3.75%	1,057,507
3.	To approve the amended Directors’ Remuneration Policy	643,346,097	87.26%	614,711,926	95.95%	25,915,697	4.05%	2,718,474
4.	To declare a final dividend of 4.70 pence per ordinary share	643,346,097	87.26%	642,966,257	99.99%	211	0.01%	379,629
5.	To elect Jurgens Myburgh as a Director	643,346,097	87.26%	640,899,142	99.68%	2,060,463	0.32%	386,492
6.	To re-elect Danie Meintjes as a Director	643,346,097	87.26%	642,864,882	99.99%	94,723	0.01%	386,492
7.	To re-elect Dr Edwin Hertzog as a Director	643,346,097	87.26%	625,998,995	97.38%	16,833,567	2.62%	513,535
8.	To re-elect Jannie Durand as a Director	643,346,097	87.26%	612,105,167	95.26%	30,444,213	4.74%	796,717
9.	To re-elect Alan Grieve as a Director	643,346,097	87.26%	640,694,983	99.93%	445,220	0.07%	2,205,894
10.	To re-elect Seamus Keating as a Director	643,346,097	87.26%	641,082,006	99.99%	46,572	0.01%	2,217,519
11.	To re-elect Prof Dr Robert Leu as a Director	643,346,097	87.26%	641,083,644	99.99%	44,934	0.01%	2,217,519
12.	To re-elect Nandi Mandela as a Director	643,346,097	87.26%	642,901,226	99.99%	49,254	0.01%	395,617
13.	To re-elect Trevor Petersen as a Director	643,346,097	87.26%	632,937,299	98.72%	8,191,279	1.28%	2,217,519
14.	To re-elect Desmond Smith as a Director	643,346,097	87.26%	639,878,832	99.87%	836,521	0.13%	2,630,744

		TOTAL SHARES VOTED	% OF ISSUED SHARE CAPITAL VOTED	VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD
15.	To re-appoint PricewaterhouseCoopers LLP as auditors of the Company	643,346,097	87.26%	642,446,940	99.99%	3,656	0.01%	895,501
16.	To authorise the Audit and Risk Committee to determine the remuneration of the auditors	643,346,097	87.26%	642,417,589	99.98%	120,859	0.02%	807,649
17.	To authorise the Directors to make political donations	643,346,097	87.26%	566,825,468	89.04%	69,771,641	10.96%	6,748,988
18.	To authorise the Directors to allot ordinary shares	643,346,097	87.26%	527,047,324	82.04%	115,391,424	17.96%	907,349
	SPECIAL RESOLUTIONS							
19.	To authorise the Directors to dis-apply the statutory pre-emption rights	643,346,097	87.26%	583,771,316	91.13%	56,840,187	8.87%	2,734,594
20.	To authorise the Directors to dis-apply pre-emption rights for purposes of acquisitions or capital investments	643,346,097	87.26%	591,889,385	93.19%	43,253,058	6.81%	8,203,654
21.	To authorise the amendment to the Articles of Association	643,346,097	87.26%	641,126,245	99.99%	1,314	0.01%	2,218,538
22.	To approve the reduction in minimum notice period for general meetings (other than annual general meetings)	643,346,097	87.26%	617,065,427	96.43%	22,854,064	3.57%	3,426,606

VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDER ON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

	ORDINARY RESOLUTIONS	TOTAL SHARES VOTED	% OF ISSUED SHARE CAPITAL VOTED	VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD
9.	To re-elect Alan Grieve as a Director	571,230,713	77.48%	568,579,599	99.92%	445,220	0.08%	2,205,894
10.	To re-elect Seamus Keating as a Director	571,230,713	77.48%	568,966,622	99.99%	46,572	0.01%	2,217,519
11.	To re-elect Prof Dr Robert Leu as a Director	571,230,713	77.48%	568,968,260	99.99%	44,934	0.01%	2,217,519
12.	To re-elect Nandi Mandela as a Director	571,230,713	77.48%	570,785,842	99.99%	49,254	0.01%	395,617
13.	To re-elect Trevor Petersen as a Director	571,230,713	77.48%	560,821,915	98.56%	8,191,279	1.44%	2,217,519
14.	To re-elect Desmond Smith as a Director	571,230,713	77.48%	567,763,448	99.85%	836,521	0.15%	2,630,744

Notes:

1. Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the "For" total.
2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
3. The Company's total ordinary shares in issue (total voting rights) as at 25 July 2017 was 737 243 810 ordinary shares of 10 pence each. Ordinary shareholders are entitled to one vote per ordinary share held.
4. As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each resolution to elect an independent non-executive director (resolutions 9 to 14) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by:
 - (a) the shareholders of the Company as a whole; and
 - (b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the controlling shareholder.

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection at <http://www.morningstar.co.uk/uk/NSM>.

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Company's website at www.mediclinic.com.

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby
+44 (0)207 954 9600

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries

FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd